Table of Contents Author Guidelines Submit a Manuscript
International Journal of Endocrinology
Volume 2014, Article ID 917813, 12 pages
http://dx.doi.org/10.1155/2014/917813
Review Article

Bariatric Endocrinology: Principles of Medical Practice

Minnesota Center for Obesity, Metabolism and Endocrinology (MNCOME), 1185 Town Centre Drive, Suite 220, Eagan, MN 55123, USA

Received 15 November 2013; Revised 19 March 2014; Accepted 11 April 2014; Published 12 May 2014

Academic Editor: Yi-Hao Yu

Copyright © 2014 J. Michael Gonzalez-Campoy et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Feneberg and P. Malfertheiner, “Epidemic trends of obesity with impact on metabolism and digestive diseases,” Digestive Diseases, vol. 30, no. 2, pp. 143–147, 2012. View at Google Scholar
  2. Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults—The Evidence Report, “National Institutes of Health,” Obesity Research, vol. 6, no. 2, pp. 51S–209S, 1998. View at Publisher · View at Google Scholar
  3. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: executive summary, “Expert panel on the identification, evaluation, and treatment of overweight in adults,” The American Journal of Clinical Nutrition, vol. 68, pp. 899–917, 1998. View at Google Scholar
  4. S. R. Smith, J. C. Lovejoy, F. Greenway et al., “Contributions of total body fat, abdominal subcutaneous adipose tissue compartments, and visceral adipose tissue to the metabolic complications of obesity,” Metabolism: Clinical and Experimental, vol. 50, no. 4, pp. 425–435, 2001. View at Publisher · View at Google Scholar · View at Scopus
  5. NIH Health implications of obesity, “National institutes of health consensus development conference statement,” Annals of Internal Medicine, vol. 103, pp. 1073–1077, 1985. View at Publisher · View at Google Scholar
  6. A. H. Mokdad, E. S. Ford, B. A. Bowman et al., “Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001,” Journal of the American Medical Association, vol. 289, no. 1, pp. 76–79, 2003. View at Publisher · View at Google Scholar · View at Scopus
  7. O. Tochikubo, E. Miyajima, K. Okabe, K. Imai, and M. Ishii, “Improvement of multiple coronary risk factors in obese hypertensives by reduction of intra-abdominal visceral fat,” Japanese Heart Journal, vol. 35, no. 6, pp. 715–725, 1994. View at Google Scholar · View at Scopus
  8. H. E. Bays, P. P. Toth, P. M. Kris-Etherton et al., “Obesity, adiposity, and dyslipidemia: a consensus statement from the National Lipid Association,” Journal of Clinical Lipidology, vol. 7, no. 4, pp. 304–383, 2013. View at Publisher · View at Google Scholar
  9. National Cholesterol Education Program Expert Panel on Detection E, Treatment of High Blood Cholesterol in A, “Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report,” Circulation, vol. 106, no. 25, pp. 3143–3421, 2002. View at Google Scholar
  10. J. I. Cleeman, “Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III),” Journal of the American Medical Association, vol. 285, no. 19, pp. 2486–2497, 2001. View at Google Scholar · View at Scopus
  11. J. M. Gonzalez-Campoy, S. T. S. Jeor, K. Castorino et al., “Clinical practice guidelines for healthy eating for the prevention and treatment of metabolic and endocrine diseases in adults: cosponsored by the American Association of Clinical Endocrinologists/the American College of Endocrinology and the Obesity Society,” Endocrine Practice: Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, vol. 19, supplement 3, pp. 1–82, 2013. View at Google Scholar
  12. H. E. Bays and J. M. Gonzalez-Campoy, “Adiposopathy,” in New-Opathies, E. Friedberg, D. H. Castrillon, R. L. Galindo, and K. Wharton, Eds., pp. 105–168, 2012. View at Google Scholar
  13. H. E. Bays, J. M. González-Campoy, G. A. Bray et al., “Pathogenic potential of adipose tissue and metabolic consequences of adipocyte hypertrophy and increased visceral adiposity,” Expert Review of Cardiovascular Therapy, vol. 6, no. 3, pp. 343–368, 2008. View at Publisher · View at Google Scholar · View at Scopus
  14. D. B. Diercks, M. T. Roe, J. Mulgund et al., “The obesity paradox in non-ST-segment elevation acute coronary syndromes: results from the Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the American College of Cardiology/American Heart Association Guidelines Quality Improvement Initiative,” American Heart Journal, vol. 152, no. 1, pp. 140–148, 2006. View at Publisher · View at Google Scholar · View at Scopus
  15. J.-P. Desprs, “Excess visceral adipose tissue/ectopic fat: the missing link in the obesity paradox?” Journal of the American College of Cardiology, vol. 57, no. 19, pp. 1887–1889, 2011. View at Publisher · View at Google Scholar · View at Scopus
  16. O. Ozeke, C. Ozer, M. Gungor, M. K. Celenk, H. Dincer, and G. Ilicin, “Chronic intermittent hypoxia caused by obstructive sleep apnea may play an important role in explaining the morbidity-mortality paradox of obesity,” Medical Hypotheses, vol. 76, no. 1, pp. 61–63, 2011. View at Publisher · View at Google Scholar · View at Scopus
  17. M. Lainscak, S. von Haehling, W. Doehner, and S. D. Anker, “The obesity paradox in chronic disease: facts and numbers,” Journal of Cachexia, Sarcopenia and Muscle, vol. 3, no. 1, pp. 1–4, 2012. View at Publisher · View at Google Scholar
  18. C. J. Lavie, A. De Schutter, D. A. Patel, A. Romero-Corral, S. M. Artham, and R. V. Milani, “Body composition and survival in stable coronary heart disease: impact of lean mass index and body fat in the ‘Obesity Paradox’,” Journal of the American College of Cardiology, vol. 60, no. 15, pp. 1374–1380, 2012. View at Publisher · View at Google Scholar
  19. P. A. McAuley, E. G. Artero, X. Sui et al., “The obesity paradox, cardiorespiratory fitness, and coronary heart disease,” Mayo Clinic Proceedings, vol. 87, pp. 443–451, 2012. View at Publisher · View at Google Scholar · View at Scopus
  20. L. Schenkeveld, M. Magro, R. M. Oemrawsingh et al., “The influence of optimal medical treatment on the 'obesity paradox', body mass index and long-term mortality in patients treated with percutaneous coronary intervention: a prospective cohort study,” BMJ Open, vol. 2, no. 1, Article ID 000535, 2012. View at Publisher · View at Google Scholar · View at Scopus
  21. M. D. Jensen, D. H. Ryan, C. M. Apovian et al., “AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association task force on practice guidelines and the obesity society,” Circulation, 2013. View at Publisher · View at Google Scholar
  22. J. I. Mechanick, R. F. Kushner, H. J. Sugerman et al., “Clinical practice guidelines for the perioperative nutritional, metabolic, and nonsurgical support of the bariatric surgery patient—2013 update: cosponsored by American Association of Clinical Endocrinologists, the Obesity Society, and American Society for Metabolic & Bariatric Surgery,” Surgery for Obesity and Related Diseases, vol. 9, pp. 159–191, 2013. View at Google Scholar
  23. P. Malaviya and C. M. Brendl, “Do hedonic motives moderate regulatory focus motives? Evidence from the framing of persuasive messages,” Journal of Personality and Social Psychology, vol. 106, pp. 1–19, 2014. View at Publisher · View at Google Scholar
  24. A. A. Witt, G. A. Raggio, M. L. Butryn, and M. R. Lowe, “Do hunger and exposure to food affect scores on a measure of hedonic hunger? An experimental study,” Appetite, vol. 74, pp. 1–5, 2014. View at Publisher · View at Google Scholar
  25. A. A. Witt and M. R. Lowe, “Hedonic hunger and binge eating among women with eating disorders,” International Journal of Eating Disorders, vol. 47, no. 3, pp. 273–280, 2014. View at Publisher · View at Google Scholar
  26. C. Zhan, J. Zhou, Q. Feng et al., “Acute and long-term suppression of feeding behavior by POMC neurons in the brainstem and hypothalamus, respectively,” The Journal of Neuroscience, vol. 33, no. 8, pp. 3624–3632, 2013. View at Publisher · View at Google Scholar
  27. J. H. Jennings, G. Rizzi, A. M. Stamatakis, R. L. Ung, and G. D. Stuber, “The inhibitory circuit architecture of the lateral hypothalamus orchestrates feeding,” Science, vol. 341, no. 6153, pp. 1517–1521, 2013. View at Publisher · View at Google Scholar
  28. S. J. Guyenet, M. E. Matsen, G. J. Morton, K. J. Kaiyala, and M. W. Schwartz, “Rapid glutamate release in the mediobasal hypothalamus accompanies feeding and is exaggerated by an obesogenic food,” Molecular Metabolism, vol. 2, no. 2, pp. 116–122, 2013. View at Publisher · View at Google Scholar
  29. T. R. Stratford and D. Wirtshafter, “Evidence that the nucleus accumbens shell, ventral pallidum, and lateral hypothalamus are components of a lateralized feeding circuit,” Behavioural Brain Research, vol. 226, no. 2, pp. 548–554, 2012. View at Publisher · View at Google Scholar · View at Scopus
  30. S. A. Brown, B. Levi, C. Lequex, V. W. Wong, A. Mojallal, and M. T. Longaker, “Basic science review on adipose tissue for clinicians,” Plastic and Reconstructive Surgery, vol. 126, no. 6, pp. 1936–1946, 2010. View at Publisher · View at Google Scholar · View at Scopus
  31. S. E. Wozniak, L. L. Gee, M. S. Wachtel, and E. E. Frezza, “Adipose tissue: The new endocrine organ? a review article,” Digestive Diseases and Sciences, vol. 54, no. 9, pp. 1847–1856, 2009. View at Publisher · View at Google Scholar · View at Scopus
  32. A. Schäffler and C. Büchler, “Concise review: adipose tissue-derived stromal cells—basic and clinical implications for novel cell-based therapies,” Stem Cells, vol. 25, no. 4, pp. 818–827, 2007. View at Publisher · View at Google Scholar · View at Scopus
  33. J. K. Sethi and A. J. Vidal-Puig, “Thematic review series: adipocyte Biology. Adipose tissue function and plasticity orchestrate nutritional adaptation,” Journal of Lipid Research, vol. 48, no. 6, pp. 1253–1262, 2007. View at Publisher · View at Google Scholar · View at Scopus
  34. M. Lopata and E. Onal, “Mass loading, sleep apnea, and the pathogenesis of obesity hypoventilation,” American Review of Respiratory Disease, vol. 126, no. 4, pp. 640–645, 1982. View at Google Scholar · View at Scopus
  35. S. Rossner, “Snoring, sleep apnea and obesity,” Acta Medica Scandinavica, vol. 221, no. 3, pp. 225–226, 1987. View at Google Scholar · View at Scopus
  36. E. H. Wittels and S. Thompson, “Obstructive sleep apnea and obesity,” Otolaryngologic Clinics of North America, vol. 23, no. 4, pp. 751–760, 1990. View at Google Scholar · View at Scopus
  37. G. A. Bray, “Medical consequences of obesity,” Journal of Clinical Endocrinology and Metabolism, vol. 89, no. 6, pp. 2583–2589, 2004. View at Publisher · View at Google Scholar · View at Scopus
  38. J. J. Anderson and D. T. Felson, “Factors associated with osteoarthritis of hte knee in the first National Health and Nutrition Examination Survey (HANES I). Evidence for an association with overweight, race, and physical demands of work,” American Journal of Epidemiology, vol. 128, no. 1, pp. 179–189, 1988. View at Google Scholar · View at Scopus
  39. M. A. Allman-Farinelli, R. J. Aitken, L. A. King, and A. E. Bauman, “Osteoarthritis—the forgotten obesity-related epidemic with worse to come,” Medical Journal of Australia, vol. 188, no. 5, p. 317, 2008. View at Google Scholar · View at Scopus
  40. R. O. Moreira, K. F. Marca, J. C. Appolinario, and W. F. Coutinho, “Increased waist circumference is associated with an increased prevalence of mood disorders and depressive symptoms in obese women,” Eating and Weight Disorders, vol. 12, no. 1, pp. 35–40, 2007. View at Google Scholar · View at Scopus
  41. D. Arterburn, E. O. Westbrook, E. J. Ludman et al., “Relationship between obesity, depression, and disability in middle-aged women,” Obesity Research and Clinical Practice, vol. 6, pp. e197–e206, 2012. View at Publisher · View at Google Scholar · View at Scopus
  42. G. E. Simon, D. Arterburn, P. Rohde et al., “Obesity, depression, and health services costs among middle-aged women,” Journal of General Internal Medicine, vol. 26, no. 11, pp. 1284–1290, 2011. View at Publisher · View at Google Scholar · View at Scopus
  43. L. B. Palmese, P. C. DeGeorge, J. C. Ratliff et al., “Insomnia is frequent in schizophrenia and associated with night eating and obesity,” Schizophrenia Research, vol. 133, no. 1–3, pp. 238–243, 2011. View at Publisher · View at Google Scholar · View at Scopus
  44. E. Incledon, M. Wake, and M. Hay, “Psychological predictors of adiposity: systematic review of longitudinal studies,” International Journal of Pediatric Obesity, vol. 6, no. 2, pp. e1–e11, 2011. View at Publisher · View at Google Scholar · View at Scopus
  45. W. Greggersen, S. Rudolf, E. Fassbinder et al., “Major depression, borderline personality disorder, and visceral fat content in women,” European Archives of Psychiatry and Clinical Neuroscience, vol. 261, no. 8, pp. 551–557, 2011. View at Publisher · View at Google Scholar · View at Scopus
  46. U. Zimmermann, T. Kraus, H. Himmerich, A. Schuld, and T. Pollmächer, “Epidemiology, implications and mechanisms underlying drug-induced weight gain in psychiatric patients,” Journal of Psychiatric Research, vol. 37, no. 3, pp. 193–220, 2003. View at Publisher · View at Google Scholar · View at Scopus
  47. American Diabetes Association, American Psychiatric Association,, American Association of Clinical Endocrinologists, and North American Association for the Study of Obesity, “Consensus development conference on antipsychotic drugs and obesity and diabetes,” Diabetes Care, vol. 27, no. 2, pp. 596–601, 2004. View at Publisher · View at Google Scholar
  48. G. P. Reynolds and S. L. Kirk, “Metabolic side effects of antipsychotic drug treatment - pharmacological mechanisms,” Pharmacology and Therapeutics, vol. 125, no. 1, pp. 169–179, 2010. View at Publisher · View at Google Scholar · View at Scopus
  49. L. V. Kessing, A. F. Thomsen, U. B. Mogensen, and P. K. Andersen, “Treatment with antipsychotics and the risk of diabetes in clinical practice,” British Journal of Psychiatry, vol. 197, no. 4, pp. 266–271, 2010. View at Publisher · View at Google Scholar · View at Scopus
  50. NIH Clinical Guidelines on the indentification, evaluation, and treatment of overweight and obesity in adults, “The evidence report,” in U.S. Department of Health and Human Services; Public Health Service; National Institutes of Health, National Heart, Lung, and Blood Institutes, 1998. View at Google Scholar
  51. D. O. Okorodudu, M. F. Jumean, V. M. Montori et al., “Diagnostic performance of body mass index to identify obesity as defined by body adiposity: a systematic review and meta-analysis,” International Journal of Obesity, vol. 34, no. 5, pp. 791–799, 2010. View at Publisher · View at Google Scholar · View at Scopus
  52. A. Shuster, M. Patlas, J. H. Pinthus, and M. Mourtzakis, “The clinical importance of visceral adiposity: a critical review of methods for visceral adipose tissue analysis,” British Journal of Radiology, vol. 85, no. 1009, pp. 1–10, 2012. View at Publisher · View at Google Scholar · View at Scopus
  53. A. Leppik, T. Jürimäe, and J. Jürimäe, “Influence of anthropometric parameters on the body composition measured by bioelectrical impedance analysis or DXA in children,” Acta Paediatrica, International Journal of Paediatrics, vol. 93, no. 8, pp. 1036–1041, 2004. View at Publisher · View at Google Scholar · View at Scopus
  54. M. D. Van Loan, “Estimates of Fat-free mass (FFM) by densitometry, dual energy X-ray absorptiometry (DXA), and Bioimpedance spectroscopy (BIS)in Caucasian and Chinese-American women,” Applied Radiation and Isotopes, vol. 49, no. 5-6, pp. 751–752, 1998. View at Publisher · View at Google Scholar · View at Scopus
  55. J. L. Clasey, C. Bouchard, C. D. Teates et al., “The use of anthropometric and dual-energy X-ray absorptiometry (DXA) measures to estimate total abdominal and abdominal visceral fat in men and women,” Obesity Research, vol. 7, no. 3, pp. 256–264, 1999. View at Google Scholar · View at Scopus
  56. M. A. Bredella, R. H. Ghomi, B. J. Thomas et al., “Comparison of DXA and CT in the assessment of body composition in premenopausal women with obesity and anorexia nervosa,” Obesity, vol. 18, no. 11, pp. 2227–2233, 2010. View at Publisher · View at Google Scholar · View at Scopus
  57. J. LaForgia, J. Dollman, M. J. Dale, R. T. Withers, and A. M. Hill, “Validation of DXA body composition estimates in obese men and women,” Obesity, vol. 17, no. 4, pp. 821–826, 2009. View at Publisher · View at Google Scholar · View at Scopus
  58. H. Bays, “Adiposopathy, metabolic syndrome, quantum physics, general relativity, chaos and the theory of everything,” Expert Review of Cardiovascular Therapy, vol. 3, no. 3, pp. 393–404, 2005. View at Publisher · View at Google Scholar · View at Scopus
  59. H. Bays, N. Abate, and M. Chandalia, “Adiposopathy: sick fat causes high blood sugar, high blood pressure and dyslipidemia,” Future Cardiol, vol. 1, no. 1, pp. 39–59, 2005. View at Publisher · View at Google Scholar
  60. H. Bays, “Adiposopathy: role of adipocyte factors in a new paradigm,” Expert Review of Cardiovascular Therapy, vol. 3, no. 2, pp. 187–189, 2005. View at Publisher · View at Google Scholar · View at Scopus
  61. H. E. Bays, J. M. González-Campoy, R. R. Henry et al., “Is adiposopathy (sick fat) an endocrine disease?” International Journal of Clinical Practice, vol. 62, no. 10, pp. 1474–1483, 2008. View at Publisher · View at Google Scholar · View at Scopus
  62. H. Bays and C. A. Dujovne, “Adiposopathy is a more rational treatment target for metabolic disease than obesity alone,” Current Atherosclerosis Reports, vol. 8, no. 2, pp. 144–156, 2006. View at Publisher · View at Google Scholar · View at Scopus
  63. MMA. Minnesota Medical Association Obesity Task Force, “How to evaluate and treat obesity,” Minnesota Medicine, vol. 88, pp. 40–46, 2005. View at Google Scholar
  64. N. Kubota, Y. Terauchi, H. Miki et al., “PPARγ mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance,” Molecular Cell, vol. 4, no. 4, pp. 597–609, 1999. View at Publisher · View at Google Scholar · View at Scopus
  65. P. Imbeault, S. Lemieux, D. Prud'homme et al., “Relationship of visceral adipose tissue to metabolic risk factors for coronary heart disease: is there a contribution of subcutaneous fat cell hypertrophy?” Metabolism: Clinical and Experimental, vol. 48, no. 3, pp. 355–362, 1999. View at Google Scholar · View at Scopus
  66. T. J. Ryan and S. B. Curri, “Hypertrophy and atrophy of fat,” Clinics in Dermatology, vol. 7, no. 4, pp. 93–106, 1989. View at Google Scholar · View at Scopus
  67. J.-P. Després, “Inflammation and cardiovascular disease: is abdominal obesity the missing link?” International Journal of Obesity, vol. 27, no. 3, pp. S22–S24, 2003. View at Publisher · View at Google Scholar · View at Scopus
  68. M. Shields, M. S. Tremblay, S. C. Gorber, and I. Janssen, “Abdominal obesity and cardiovascular disease risk factors within body mass index categories,” Health Reports, vol. 23, no. 2, pp. 7–15, 2012. View at Google Scholar
  69. M. A. Kamimura, J. J. Carrero, M. E. Canziani, R. Watanabe, M. M. Lemos, and L. Cuppari, “Visceral obesity assessed by computed tomography predicts cardiovascular events in chronic kidney disease patients,” Nutrition, Metabolism and Cardiovascular Diseases, vol. 23, no. 9, pp. 891–897, 2012. View at Publisher · View at Google Scholar
  70. L. J. Aronne, D. S. Nelinson, and J. L. Lillo, “Obesity as a disease state: A new paradigm for diagnosis and treatment,” Clinical Cornerstone, vol. 9, no. 4, pp. 9–29, 2009. View at Publisher · View at Google Scholar · View at Scopus
  71. V. A. Moyer, “Screening for and management of obesity in adults: U.S. preventive services task force recommendation statement,” Annals of Internal Medicine, vol. 17, no. 5, pp. 1–32, 2012. View at Google Scholar
  72. R. F. Kushner and R. L. Weinsier, “Evaluation of the obese patient: practical considerations,” Medical Clinics of North America, vol. 84, no. 2, pp. 387–399, 2000. View at Google Scholar · View at Scopus
  73. A. J. Garber, M. J. Abrahamson, J. I. Barzilay et al., “AACE comprehensive diabetes management algorithm,” Endocrine Practice, vol. 19, pp. 327–336, 2013. View at Google Scholar
  74. American Society of Bariatric Physicians Obesity Algorithm: Adult Adiposity Evaluation and Treatment, 2013.
  75. NDEP, “Guiding principles for diabetes care: for health care professionals,” in National Diabetes Education Program, 2009. View at Google Scholar
  76. R. Gutierrez, M. K. Lobo, F. Zhang, and L. De Lecea, “Neural integration of reward, arousal, and feeding: recruitment of VTA, lateral hypothalamus, and ventral striatal neurons,” IUBMB Life, vol. 63, no. 10, pp. 824–830, 2011. View at Publisher · View at Google Scholar · View at Scopus
  77. M. F. Wiater, S. Mukherjee, A.-J. Li et al., “Circadian integration of sleep-wake and feeding requires NPY receptorexpressing neurons in the mediobasal hypothalamus,” American Journal of Physiology, Regulatory Integrative and Comparative Physiology, vol. 301, no. 5, pp. 1569–1583, 2011. View at Publisher · View at Google Scholar · View at Scopus
  78. K. W. Williams and J. K. Elmquist, “Lighting up the hypothalamus: coordinated control of feeding behavior,” Nature Neuroscience, vol. 14, no. 3, pp. 277–278, 2011. View at Publisher · View at Google Scholar · View at Scopus
  79. D. Leroith, “Foreword. Control of feeding behavior and the peripheral metabolism by the hypothalamus,” Endocrinology and metabolism clinics of North America, vol. 37, no. 4, pp. 11–13, 2008. View at Publisher · View at Google Scholar
  80. L. M. Oyama, C. M. O. D. Nascimento, J. Carnier et al., “The role of anorexigenic and orexigenic neuropeptides and peripheral signals on quartiles of weight loss in obese adolescents,” Neuropeptides, vol. 44, no. 6, pp. 467–474, 2010. View at Publisher · View at Google Scholar · View at Scopus
  81. J. Carnier, A. De Piano, P. De Lima Sanches et al., “The role of orexigenic and anorexigenic factors in an interdisciplinary weight loss therapy for obese adolescents with symptoms of eating disorders,” International Journal of Clinical Practice, vol. 64, no. 6, pp. 784–790, 2010. View at Publisher · View at Google Scholar · View at Scopus
  82. N. A. King, P. P. Caudwell, M. Hopkins, J. R. Stubbs, E. Naslund, and J. E. Blundell, “Dual-process action of exercise on appetite control: increase in orexigenic drive but improvement in meal-induced satiety,” American Journal of Clinical Nutrition, vol. 90, no. 4, pp. 921–927, 2009. View at Publisher · View at Google Scholar · View at Scopus
  83. S. C. Benoit, A. L. Tracy, J. F. Davis, D. Choi, and D. J. Clegg, “Novel functions of orexigenic hypothalamic peptides: from genes to behavior,” Nutrition, vol. 24, no. 9, pp. 843–847, 2008. View at Publisher · View at Google Scholar · View at Scopus
  84. K. Diepvens, D. Häberer, and M. Westerterp-Plantenga, “Different proteins and biopeptides differently affect satiety and anorexigenic/orexigenic hormones in healthy humans,” International Journal of Obesity, vol. 32, no. 3, pp. 510–518, 2008. View at Publisher · View at Google Scholar · View at Scopus
  85. J. Menyhért, G. Wittmann, E. Hrabovszky, É. Keller, Z. Liposits, and C. Fekete, “Interconnection between orexigenic neuropeptide Y- and anorexigenic α-melanocyte stimulating hormone-synthesizing neuronal systems of the human hypothalamus,” Brain Research, vol. 1076, no. 1, pp. 101–105, 2006. View at Publisher · View at Google Scholar · View at Scopus
  86. R. H. Mak, W. Cheung, R. D. Cone, and D. L. Marks, “Orexigenic and anorexigenic mechanisms in the control of nutrition in chronic kidney disease,” Pediatric Nephrology, vol. 20, no. 3, pp. 427–431, 2005. View at Publisher · View at Google Scholar · View at Scopus
  87. Y. Takimoto, A. Inui, H. Kumano, and T. Kuboki, “Orexigenic/anorexigenic signals in Bulimia nervosa,” Current Molecular Medicine, vol. 3, no. 4, pp. 349–360, 2003. View at Publisher · View at Google Scholar · View at Scopus
  88. S. E. Shaffer and B. J. Tepper, “Effects of learned flavor cues on single meal and daily food intake in humans,” Physiology and Behavior, vol. 55, no. 6, pp. 979–986, 1994. View at Publisher · View at Google Scholar · View at Scopus
  89. D. A. Levitsky, “The non-regulation of food intake in humans: hope for reversing the epidemic of obesity,” Physiology and Behavior, vol. 86, no. 5, pp. 623–632, 2005. View at Publisher · View at Google Scholar · View at Scopus
  90. R. C. Post, J. Eder, S. Maniscalco, D. Johnson-Bailey, and S. Bard, “MyPlate is now reaching more consumers through social media,” Journal of the Academy of Nutrition and Dietetics, vol. 113, no. 6, pp. 754–755, 2013. View at Publisher · View at Google Scholar
  91. M. Ackley, “MyPlate—make it great!,” Ohio Nurses Review, vol. 87, p. 4, 2012. View at Google Scholar
  92. R. Post, J. Haven, and S. Maniscalco, “Putting MyPlate to work for nutrition educators,” Journal of Nutrition Education and Behavior, vol. 44, no. 2, pp. 98–99, 2012. View at Publisher · View at Google Scholar · View at Scopus
  93. J. McCaffree, “Position of the American Dietetic Association: integration of medical nutrition therapy and pharmacotherapy,” Journal of the American Dietetic Association, vol. 103, no. 10, pp. 1363–1370, 2003. View at Publisher · View at Google Scholar · View at Scopus
  94. N. Durant and J. Cox, “Current treatment approaches to overweight in adolescents,” Current Opinion in Pediatrics, vol. 17, no. 4, pp. 454–459, 2005. View at Publisher · View at Google Scholar · View at Scopus
  95. A. Frank, “A multidisciplinary approach to obesity management: the physician's role and team care alternatives,” Journal of the American Dietetic Association, vol. 98, no. 10, pp. S44–S48, 1998. View at Publisher · View at Google Scholar · View at Scopus
  96. J. M. Ashley, S. T. S. Jeor, J. P. Schrage et al., “Weight control in the physician's office,” Archives of Internal Medicine, vol. 161, no. 13, pp. 1599–1604, 2001. View at Google Scholar · View at Scopus
  97. M. C. Battista, M. Labonte, J. Menard et al., “Dietitian-coached management in combination with annual endocrinologist follow up improves global metabolic and cardiovascular health in diabetic participants after 24 months,” Applied Physiology, Nutrition, and Metabolism, vol. 37, no. 4, pp. 610–620, 2012. View at Publisher · View at Google Scholar
  98. S. Cummings, E. S. Parham, and G. W. Strain, “Position of the American Dietetic Association: weight management,” Journal of the American Dietetic Association, vol. 102, no. 8, pp. 1145–1155, 2002. View at Publisher · View at Google Scholar · View at Scopus
  99. A. R. Gabriel, “Shedding pounds for life. How a dietitian can help. In the war against weight gain, a registered dietitian can be your most important ally,” Diabetes forecast, vol. 56, no. 4, pp. 93–94, 2003. View at Google Scholar · View at Scopus
  100. L. A. Leiter, “A dietitian-led intervention reduced weight and waist circumference in obese patients with type 2 diabetes,” ACP Journal Club, vol. 142, no. 1, p. 17, 2005. View at Google Scholar
  101. K. S. Rhodes, L. C. Bookstein, L. S. Aaronson, N. M. Mercer, and C. E. Orringer, “Intensive nutrition counseling enhances outcomes of national cholesterol education program dietary therapy,” Journal of the American Dietetic Association, vol. 96, no. 10, pp. 1003–1010, 1996. View at Publisher · View at Google Scholar · View at Scopus
  102. T. L. Taillefer, “Nurses and dietitians collaborating to impact nutrition and diabetes mellitus management issues for patients with type 2 diabetes mellitus on hemodialysis,” Nephrology Nursing Journal: Journal of the American Nephrology Nurses' Association, vol. 35, no. 5, pp. 503–505, 2008. View at Google Scholar · View at Scopus
  103. F. K. Welty, M. M. Nasca, N. S. Lew, S. Gregoire, and Y. Ruan, “Effect of onsite dietitian counseling on weight loss and lipid levels in an outpatient physician office,” American Journal of Cardiology, vol. 100, no. 1, pp. 73–75, 2007. View at Publisher · View at Google Scholar · View at Scopus
  104. K. Johansson, K. Neovius, S. M. DeSantis, S. Rössner, and M. Neovius, “Discontinuation due to adverse events in randomized trials of orlistat, sibutramine and rimonabant: a meta-analysis,” Obesity Reviews, vol. 10, no. 5, p. 586, 2009. View at Publisher · View at Google Scholar · View at Scopus
  105. D. Taylor, “Withdrawal of rimonabant—walking the tightrope of 21st century pharmaceutical regulation?” Current Drug Safety, vol. 4, no. 1, pp. 2–4, 2009. View at Publisher · View at Google Scholar · View at Scopus
  106. S. Czernichow and D. Batty, “Editorial: Withdrawal of sibutramine for weight loss: where does this leave clinicians?” Obesity Facts, vol. 3, no. 3, pp. 155–156, 2010. View at Publisher · View at Google Scholar · View at Scopus
  107. G. Williams, “Withdrawal of sibutramine in Europe,” BMJ, vol. 340, p. c824, 2010. View at Publisher · View at Google Scholar · View at Scopus
  108. A. Sayburn, “Withdrawal of sibutramine leaves European doctors with just one obesity drug,” BMJ, vol. 340, p. c477, 2010. View at Publisher · View at Google Scholar · View at Scopus
  109. L. S. Barak, A. Salahpour, X. Zhang et al., “Pharmacological characterization of membrane-expressed human trace amine-associated receptor 1 (TAAR1) by a bioluminescence resonance energy transfer cAMP biosensor,” Molecular Pharmacology, vol. 74, no. 3, pp. 585–594, 2008. View at Publisher · View at Google Scholar · View at Scopus
  110. J. Yelnosky, R. E. Panasevich, A. R. Borrelli, and R. B. Lawlor, “Pharmacology of phentermine,” Archives internationales de pharmacodynamie et de therapie, vol. 178, no. 1, pp. 62–76, 1969. View at Google Scholar · View at Scopus
  111. R. B. Lawlor, M. C. Trivedi, and J. Yelnosky, “A determination of the anorexigenic potential of dl-amphetamine, d-amphetamine, l-amphetamine and phentermine,” Archives internationales de pharmacodynamie et de therapie, vol. 179, no. 2, pp. 401–407, 1969. View at Google Scholar · View at Scopus
  112. K. W. Sehnert, “Development of phentermine, an appetite-control drug,” Clinical medicine, vol. 70, pp. 400–403, 1963. View at Google Scholar · View at Scopus
  113. B. A. Becker, “Pharmacologic activity of phentermine (Phenyl-t-butylamine),” Toxicology and Applied Pharmacology, vol. 3, no. 2, pp. 256–259, 1961. View at Google Scholar · View at Scopus
  114. R. B. Rothman, M. H. Baumann, C. M. Dersch et al., “Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin,” Synapse, vol. 39, pp. 32–41, 2001. View at Google Scholar
  115. E. J. Hendricks and F. L. Greenway, “A study of abrupt phentermine cessation in patients in a weight management program,” American Journal of Therapeutics, vol. 18, no. 4, pp. 292–299, 2011. View at Publisher · View at Google Scholar · View at Scopus
  116. J. S. Torgerson, J. Hauptman, M. N. Boldrin, and L. Sjöström, “XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients,” Diabetes Care, vol. 27, no. 3, p. 856, 2004. View at Publisher · View at Google Scholar · View at Scopus
  117. M. C. Mancini and A. Halpern, “Orlistat in the prevention of diabetes in the obese patient,” Vascular Health and Risk Management, vol. 4, no. 2, pp. 325–336, 2008. View at Google Scholar · View at Scopus
  118. Y. H. Zhou, X. Q. Ma, C. Wu et al., “Effect of anti-obesity drug on cardiovascular risk factors: a systematic review and meta-analysis of randomized controlled trials,” PLoS ONE, vol. 7, no. 6, Article ID e39062, 2012. View at Publisher · View at Google Scholar
  119. S. Henness and C. M. Perry, “Orlistat: a review of its use in the management of obesity,” Drugs, vol. 66, no. 12, pp. 1625–1656, 2006. View at Publisher · View at Google Scholar · View at Scopus
  120. S. O'Meara, R. Riemsma, L. Shirran, L. Mather, and G. Ter Riet, “A systematic review of the clinical effectiveness of orlistat used for the management of obesity,” Obesity Reviews, vol. 5, no. 1, pp. 51–68, 2004. View at Publisher · View at Google Scholar · View at Scopus
  121. C. K. Martin, L. M. Redman, J. Zhang et al., “Lorcaserin, a 5-HT2C receptor agonist, reduces body weight by decreasing energy intake without influencing energy expenditure,” Journal of Clinical Endocrinology and Metabolism, vol. 96, no. 3, pp. 837–845, 2011. View at Publisher · View at Google Scholar · View at Scopus
  122. W. J. Thomsen, A. J. Grottick, F. Menzaghi et al., “Lorcaserin, a novel selective human 5-hydroxytryptamine2C agonist: in vitro and in vivo pharmacological characterization,” Journal of Pharmacology and Experimental Therapeutics, vol. 325, no. 2, pp. 577–587, 2008. View at Publisher · View at Google Scholar · View at Scopus
  123. S. R. Smith, N. J. Weissman, C. M. Anderson et al., “Multicenter, placebo-controlled trial of lorcaserin for weight management,” The New England Journal of Medicine, vol. 363, no. 3, pp. 245–256, 2010. View at Publisher · View at Google Scholar · View at Scopus
  124. M. C. Fidler, M. Sanchez, B. Raether et al., “A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM Trial,” Journal of Clinical Endocrinology and Metabolism, vol. 96, no. 10, pp. 3067–3077, 2011. View at Publisher · View at Google Scholar · View at Scopus
  125. P. M. O'Neil, S. R. Smith, N. J. Weissman et al., “Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study,” Obesity, vol. 20, pp. 1426–1436, 2012. View at Publisher · View at Google Scholar · View at Scopus
  126. E. W. Chan, Y. He, C. S. Chui, A. Y. Wong, W. C. Lau, and I. C. Wong, “Efficacy and safety of lorcaserin in obese adults: a meta-analysis of 1-year randomized controlled trials (RCTs) and narrative review on short-term RCTs,” Obesity Reviews, vol. 14, no. 5, pp. 383–392, 2013. View at Publisher · View at Google Scholar
  127. D. B. Allison, K. M. Gadde, W. T. Garvey et al., “Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP),” Obesity, vol. 20, no. 2, pp. 330–342, 2012. View at Publisher · View at Google Scholar · View at Scopus
  128. H. Bays, “Phentermine, topiramate and their combination for the treatment of adiposopathy ('sick fat) and metabolic disease,” Expert Review of Cardiovascular Therapy, vol. 8, no. 12, pp. 1777–1801, 2010. View at Publisher · View at Google Scholar · View at Scopus
  129. K. M. Gadde, D. B. Allison, D. H. Ryan et al., “Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial,” The Lancet, vol. 377, no. 9774, pp. 1341–1352, 2011. View at Publisher · View at Google Scholar · View at Scopus
  130. T. Saito, M. Murata, T. Otani, H. Tamemoto, M. Kawakami, and S.-E. Ishikawa, “Association of subcutaneous and visceral fat mass with serum concentrations of adipokines in subjects with type 2 diabetes mellitus,” Endocrine Journal, vol. 59, no. 1, pp. 39–45, 2012. View at Publisher · View at Google Scholar · View at Scopus
  131. A. Michaud, R. Drolet, S. Noël, G. Paris, and A. Tchernof, “Visceral fat accumulation is an indicator of adipose tissue macrophage infiltration in women,” Metabolism: Clinical and Experimental, vol. 61, no. 5, pp. 689–698, 2012. View at Publisher · View at Google Scholar · View at Scopus
  132. X. Li, M. Katashima, T. Yasumasu, and K. J. Li, “Visceral fat area, waist circumference and metabolic risk factors in abdominally obese Chinese adults,” Biomedical and Environmental Sciences, vol. 25, pp. 141–148, 2012. View at Google Scholar
  133. J. Lee, D.-S. Chung, J.-H. Kang, and B.-Y. Yu, “Comparison of visceral fat and liver fat as risk factors of metabolic syndrome,” Journal of Korean Medical Science, vol. 27, no. 2, pp. 184–189, 2012. View at Publisher · View at Google Scholar · View at Scopus
  134. F. Item and D. Konrad, “Visceral fat and metabolic inflammation: the portal theory revisited,” Obesity Reviews, vol. 13, supplement 2, pp. 30–39, 2012. View at Publisher · View at Google Scholar
  135. C. S. Hung, C. Y. Yang, H. J. Hsieh, J. N. Wei, W. Y. Ma, and H. Y. Li, “BMI correlates better to visceral fat and insulin sensitivity than BAI,” Obesity, vol. 20, no. 6, p. 1141, 2012. View at Publisher · View at Google Scholar